CN102614140B - Iloperidone oral cavity disintegration tablet and preparation method thereof - Google Patents
Iloperidone oral cavity disintegration tablet and preparation method thereof Download PDFInfo
- Publication number
- CN102614140B CN102614140B CN201110034683.9A CN201110034683A CN102614140B CN 102614140 B CN102614140 B CN 102614140B CN 201110034683 A CN201110034683 A CN 201110034683A CN 102614140 B CN102614140 B CN 102614140B
- Authority
- CN
- China
- Prior art keywords
- iloperidone
- subsequent use
- microns
- mix homogeneously
- take
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LOKKEIOVXCRZAK-UHFFFAOYSA-N CC(c(cc1)cc(OC)c1OCCCN(CC1)CCC1c1n[o]c2c1CCCC(F)=C2)=O Chemical compound CC(c(cc1)cc(OC)c1OCCCN(CC1)CCC1c1n[o]c2c1CCCC(F)=C2)=O LOKKEIOVXCRZAK-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical preparation, be specially a kind of iloperidone oral disintegrating tablet formulation.This oral disintegrating tablet formulation with iloperidone or its pharmaceutically acceptable active salt for active component, its prescription component and weight ratio as follows: iloperidone 2 ~ 30%, filler 40 ~ 80%, disintegrating agent 1 ~ 15%, lubricant 0 ~ 3%, fluidizer 0 ~ 3%, correctives 0 ~ 10%, binding agent 0 ~ 20%.Meanwhile, the invention provides the preparation method of described oral disintegrating tablet formulation, active raw materials mixed homogeneously with partial supplementary material elder generation in preparation process, size controlling is less than 45 microns at 99% particle diameter by comminution by gas stream, and 90% is less than 20 microns.The iloperidone oral cavity disintegration tablet disintegrate that the present invention obtains is fast, and stripping is rapid, and disintegration time is 2 ~ 40 seconds, good mouthfeel, and without sand type, bioavailability is high, can comply with the dosing requirements of schizophrenic patients, and preparation technology is simple, is applicable to large-scale production.
Description
Technical field:
The present invention relates to a kind of pharmaceutical preparation, be specially oral cavity disintegration tablet of a kind of psychosis class pharmaceutical preparation and preparation method thereof.
Background technology
According to statistics, the whole world about has 400,000,000 people to suffer from the different mental disorder of weight at present, and it has become first of the large kinds of Diseases in the world ten.Mental disorder is the same with cardiovascular and cerebrovascular vessel, respiratory system disease and malignant tumor, becomes one of several large disease occurred frequently of China.Understand according to investigations, China psychotic about has 1,600 ten thousand people, and the sickness rate of mental disorder is in rising trend at home, about has 250,000 people to die from suicide every year.Schizophrenia is the one that in mental sickness, prevalence is the highest, and the sickness rate in city is apparently higher than rural area, and according to statistics, China's prevalence of schizophrenia reaches 6.55%, and patient has 7,800,000 more than.Schizophrenia is that one is separated with ergasia and actual environment, the characteristic symptom of cognitive process, affective process, will process inharmonious, mutual division is mutually outstanding behaviours, and also reflects the psychosis of other symptoms of " division " feature to a certain extent with hallucination, vain hope, tension syndrome etc.The market of antipsychotic drug (call anti-essence in the following text and divide medicine) is through exploitation for many years, quite ripe.2006, anti-essence divided medicine to reach 16,200,000,000 dollars in the sales volume of world market, became global the fifth-largest medicine classification.
At present, " atypia " of psychosis medication becomes clear day by day, by 2008, the whole world has 13 atypical antipsychotic listings, wherein there are 7 in Discussion on Chinese Listed, the gone on the market Paliperidone of clozapine for many years and fresh market and olanzapine, risperidone, Quetiapine, Aripiprazole and Ziprasidone respectively.In China, atypical antipsychotic has become a clinical line medication in recent years, the sales volume of the large kind of risperidone, olanzapine, Quetiapine, Aripiprazole and Ziprasidone five has accounted for 95% of domestic psychosis prescription drug market, this 5 large kind strides into " cookle " rank every year 2008, within 2008, global annual sales amount reaches 46.9 hundred million, 34.4 hundred million, 44.5 hundred million, 21.5 hundred million and 10.1 hundred million dollars respectively.At home, 5 large kind sample hospital gross sales amounts also reach 2.876 hundred million yuan, account for 96.6% of psychosis market, and the 5 large kinds annual rate of growth of 2008 73.6% also becomes the primary factor of antipsychotic drug rapid growth.
Although Drug safety significantly improves, still there are some problems in existing Atypical neuro leptic, as very difficult radical curing of disease, need to take medicine even all the life for a long time, major mood disease medicament less effective, drug withdrawal are easily recurred etc., therefore, industry expects that the research of antipsychotic drugs novel form, novel targets etc. can have larger breakthrough.Iloperidone (English common name: iloperidone) is schizoid first the gene target medicine for the treatment of, and this medicine has carried out 35 three phases clinical researches, and sum, more than 3000 people, confirms that it has good curative effect.Develop this medicine and will bring good economic benefit and market prospect.
Yi Panli ketone, chemical name: 1-[4-[3-[4-(fluoro-1, the 2-benzoisoxazole-3-base of 6-)-piperidino] propoxyl group]-3-methoxyphenyl] ethyl ketone, structural formula:
Molecular formula: C
24h
27fN
2o
4, molecular weight: 426.48, can not be water-soluble, is atomicly dissolved in 0.1mol/l hydrochloric acid, soluble in chloroform, ethanol, methanol, acetonitrile, is the crystalline powder between white or off-white color.US Patent No. RE39198 discloses and protects iloperidone and preparation method thereof, give also the application of iloperidone as treatment antipsychotic drugs simultaneously.
Present listing iloperidone be ordinary tablet, need swallow or send water to swallow, due to the limitation of the symptoms of schizophrenia, patient is reluctant independently to complete swallowing act, likely mismatch treatment, the treatment for disease brings very large difficulty, and oral cavity disintegration tablet solves this difficult problem just.Oral cavity disintegration tablet is the novel form of the quick-acting effect of performance occurred in recent years, compared with ordinary tablet, this dosage form without the need to water also without the need to chewing, medicine is put into mouth and is met saliva and rapid disintegrate, mouthfeel is good, without grittiness, stomach onset can be entered by simple swallowing act, greatly comply with the feature of taking medicine of schizophrenic patients.What iloperidone went on the market in the U.S. is ordinary tablet preparation, and commodity are called " FANAPT ", and specification is respectively 1mg, 2mg, 4mg, 6mg, 8mg, 10mg, 12mg.The 12mg conventional tablet of the present invention to listing carries out stripping investigation, finds that it just can reach complete stripping at 15 minutes, and for having no it and add cosolvent in the description of its preparation conventional tablet of going on the market.The object of this invention is to provide the dosage form that a kind of iloperidone is new, i.e. oral cavity disintegration tablet (oral cavity disintegration tablet), this dosage form can reach the identical or higher bioavailability with listing ordinary preparation, greatly can comply with again the particular/special requirement of patient, solves the problem of difficulty of taking medicine.
Because iloperidone can not be water-soluble, the chemical property of the atomic 0.1mol/l of being dissolved in hydrochloric acid defines this medicine can not onset immediately, and therefore its oral cavity disintegration tablet form needs according to its characteristic, and disintegrate rapidly again can at Fast Stripping in vivo in mouth to make it, improve dissolution, play drug effect.General oral tablet all adds sodium lauryl sulphate, and what have also adds tween to increase the release of medicine thus to improve bioavailability, but they exist toxicity in various degree, also have impact on oral mouthfeel simultaneously.And as oral cavity disintegration tablet, mouthfeel is also a very important index.In order to address this problem, improve dissolution rate, the adjuvant that crude drug and part have good taste is mixed homogeneously by the present invention in process simultaneously, again mixture is pulverized by high pressure draught, strict control size, 99% is less than 45 microns, and 90% is less than 20 microns.The present invention investigates evaluation by modes such as oral cavity disintegration tablet dissolution and disintegration time measuring, ocular estimate, the evaluations of volunteer mouthfeel, not only stripping is rapid to find iloperidone oral cavity disintegration tablet provided by the invention, short and the good mouthfeel of disintegration time, has greatly complied with the pathological characteristic of schizophrenic patients.Meanwhile, preparation method of the present invention is simple, is easy to large-scale production.
Summary of the invention
An object of the present invention is to provide the new dosage form of a kind of iloperidone, i.e. iloperidone oral cavity disintegration tablet.Said preparation release is fast, in the oral cavity disintegrate rapidly, and mouthfeel is good, without grittiness, without the need to drinking water, just can in stomach by simple swallowing act, and the preparation that applicable schizophrenic patients takes; And bioavailability is high, preparation technology is simple, is applicable to suitability for industrialized production.
In order to achieve the above object, iloperidone oral cavity disintegration tablet of the present invention, its active component is iloperidone or its pharmaceutically acceptable active salt, its prescription component and percentage by weight as follows:
Iloperidone or its pharmaceutically acceptable active salt 2 ~ 30%
Filler 40 ~ 80%
Disintegrating agent 1 ~ 15%
Lubricant 0 ~ 3%
Fluidizer 0 ~ 3%
Correctives 0 ~ 10%
Binding agent 0 ~ 20%
Wherein, iloperidone or its pharmaceutically acceptable active salt are principal agent, and all the other additives are adjuvant.
Further, described filler is selected from the compositions of one or more in mannitol, xylitol, sorbitol, microcrystalline Cellulose, starch, lactose.
Further, described bonding agent is selected from the one in hypromellose, PVP, starch, ethanol, purified water, crosslinked carboxymethyl fecula sodium
Further, described disintegrating agent be selected from that carboxymethyl starch is received, the compositions of one or more in cross-linked pvp or cross-linking sodium carboxymethyl cellulose.
Further, described lubricant is selected from the compositions of one or more in magnesium stearate, stearic acid, Pulvis Talci.
Further, described fluidizer can be micropowder silica gel.
In order to increase mouthfeel, iloperidone oral cavity disintegration tablet of the present invention can also add correctives, and described correctives is selected from the compositions of one or more in aspartame, acesulfame potassium, stevioside, strawberry essence, Mint Essence.
Wherein, PVP is polyvinyl pyrrolidone; Acesulfame potassium is acesulfame potassium, i.e. acesulfame potassium.
Another object of the present invention is to provide a kind of preparation method of iloperidone oral cavity disintegration tablet.
Described preparation method is as follows:
Principal agent raw material and partial supplementary material mix homogeneously are carried out pulverization process, prepares granule; Filler remaining in prescription is prepared granule; Two kinds of granules are mixed homogeneously with other adjuvants in prescription, then tabletting.
Further, the mode of described pulverization process is preferably comminution by gas stream, and after pulverizing, raw material particle size controls to be less than 45 microns at 99% particle diameter, and 90% is less than 20 microns.
Further, the described method preparing granule is wet granulation, then dries, or dry granulation.
Further, in described sheeting operation, Stress control is 30N ~ 60N.
Preferably, described partial supplementary material is filler and/or correctives.
Further, the preferred implementation that prepared by described iloperidone oral cavity disintegration tablet is specially:
1) by iloperidone, one or more are mixed homogeneously with mannitol, xylitol, sorbitol, acesulfame potassium, and by comminution by gas stream, size controlled to be less than 45 microns at 99% particle diameter, 90% is less than 20 microns, is prepared into 16 ~ 28 object granules, for subsequent use;
2) by filler mixing remaining in prescription, 16 ~ 28 object granules are prepared into, for subsequent use;
3) take the above-mentioned two kinds of granules of recipe quantity, then add recipe quantity correctives, disintegrating agent, fluidizer, mix lubricant evenly, tabletting.
The oral cavity disintegration tablet disintegrate that the present invention obtains is rapid, release is fast, disintegrate completely, can discharge completely in 10 minutes in 2 ~ 40 seconds, can onset in time, good mouthfeel, without grittiness, without sense of discomfort, substantially increase bioavailability, complied with the requirement of schizophrenic patients, and preparation technology is simple, is applicable to large-scale production.
Detailed description of the invention
In order to understand the present invention further, below in conjunction with embodiment, iloperidone oral cavity disintegration tablet provided by the invention and preparation method thereof is described in detail.
It is to be appreciated that these embodiments describe just for further describing feature of the present invention, instead of the restriction to the scope of the invention or the claims in the present invention scope.
The present invention evaluates the outward appearance of the sample that each embodiment obtains simultaneously, and attempts evaluating the mouthfeel of sample by volunteer, and evaluation index is as follows:
Ocular estimate index is as follows:
Excellent: surface is very bright and clean, smooth
Good: surface is brighter and cleaner, smooth
General: any surface finish is smooth
Difference: surface is not bright and clean, smooth
Mouthfeel (comprising sugariness, grittiness, comfort etc.) comprehensive evaluation index is as follows:
Excellent: sugariness is moderate, mouthfeel as snug as a bug in a rug
Good: sugariness is moderate, mouthfeel is more comfortable
General: sugariness is moderate, comfortable taste
Difference: mouthfeel is uncomfortable, has grains of sand sense
Embodiment 1:
Take iloperidone 24g in the present embodiment prescription ratio (iloperidone: mannitol is 12: 20) to mix homogeneously with mannitol 40g, particle size range controls to be less than 45 microns 99% by comminution by gas stream, and 90% is less than 20 microns, for subsequent use.Take the material 32g for subsequent use crushed, be prepared into 20 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Take microcrystalline Cellulose 20g, xylitol 30g mix homogeneously again, be prepared into 20 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added aspartame 2g, flavoring orange essence 1g, crosslinked pvp8g, magnesium stearate 1g, micropowder silica gel 1g, mix homogeneously, the heavy 95mg tabletting of controlled pressure 45N, sheet, theoretical amount is 1000.
Outward appearance: good
Mouthfeel: excellent
Embodiment 2:
Take iloperidone 24g in the present embodiment prescription ratio (iloperidone: xylitol is 12: 30) to mix homogeneously with mannitol 60g, particle size range controls to be less than 45 microns 99% by comminution by gas stream, and 90% is less than 20 microns, for subsequent use.Take the material 42g for subsequent use crushed, be prepared into 24 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Take microcrystalline Cellulose 20g, mannitol 30g mix homogeneously again, be prepared into 24 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added acesulfame potassium 2g, flavoring orange essence 1g, crosslinked pvp8g, Pulvis Talci 2g, micropowder silica gel 1g, mix homogeneously, the heavy 106mg tabletting of controlled pressure 37N, sheet, theoretical amount is 1000.
Outward appearance: good
Mouthfeel: excellent
Embodiment 3:
Take iloperidone 24g in the present embodiment prescription ratio (iloperidone: sorbitol is 12: 40) to mix homogeneously with mannitol 80g, particle size range controls to be less than 45 microns 99% by comminution by gas stream, and 90% is less than 20 microns, for subsequent use.Take the material 52g for subsequent use crushed, be prepared into 24 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Take microcrystalline Cellulose 20g, lactose 10g, mannitol 30g mix homogeneously again, be prepared into 24 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added acesulfame potassium 2g, Mint Essence 1g, carboxymethyl starch sodium 15g, magnesium stearate 3g, micropowder silica gel 1g, mix homogeneously, the heavy 134mg tabletting of controlled pressure 42N, sheet, theoretical amount is 1000.
Outward appearance: good
Mouthfeel: excellent
Embodiment 4:
Take iloperidone 2g in the present embodiment prescription ratio (iloperidone: sorbitol weight ratio is 1: 10) to mix homogeneously with mannitol 20g, particle size range controls to be less than 30 microns 99% by comminution by gas stream, and 90% is less than 5 microns, for subsequent use.Take the material 12g for subsequent use crushed, be prepared into 20 order granules with 10% starch slurry as bonding agent, dry for standby; Take microcrystalline Cellulose 10g, mannitol 5g mix homogeneously again, be prepared into 20 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added acesulfame potassium 1g, Mint Essence 0.5g, carboxymethyl starch sodium 4g, magnesium stearate 1g, micropowder silica gel 0.5g, mix homogeneously, the heavy 34mg tabletting of controlled pressure 45N, sheet, theoretical amount is 1000.
Outward appearance: general
Mouthfeel: outstanding
Embodiment 5:
Iloperidone 12g, mannitol 60g, acesulfame potassium 2g mix homogeneously is taken in the present embodiment prescription ratio (iloperidone: mannitol: acesulfame potassium is 6: 30: 1), particle size range controls to be less than 45 microns 99% by comminution by gas stream, 90% is less than 20 microns, for subsequent use.Take the material 37g for subsequent use crushed, be prepared into 24 order granules with 5%PVP alcoholic solution as bonding agent, dry for standby; Take microcrystalline Cellulose 20g, xylitol 15g mix homogeneously again, be prepared into 24 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added acesulfame potassium 2g, stevioside 1g, cross-linked pvp 10g, magnesium stearate 3g, micropowder silica gel 1g, mix homogeneously, the heavy 89mg tabletting of controlled pressure 39N, sheet, theoretical amount is 1000.
Outward appearance: good
Mouthfeel: good
Embodiment 6:
Iloperidone 12g, mannitol 40g, acesulfame potassium 3g mix homogeneously is taken in the present embodiment prescription ratio (iloperidone: mannitol: acesulfame potassium weight ratio is 12: 20: 1.5), particle size range controls to be less than 45 microns 99% by comminution by gas stream, 90% is less than 20 microns, for subsequent use.Take the material 27.5g for subsequent use crushed, be prepared into 24 order granules with 5% hypromellose as bonding agent, dry for standby; Take microcrystalline Cellulose 20g, mannitol 20g, aspartame 1 gram of mix homogeneously again, be prepared into 24 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added cross-linking sodium carboxymethyl cellulose 10g, magnesium stearate 3g, micropowder silica gel 1g, mix homogeneously, the heavy 82.5mg tabletting of controlled pressure 42N, sheet, theoretical amount is 1000.
Outward appearance: good
Mouthfeel: excellent
Embodiment 7:
Take iloperidone 24g in the present embodiment prescription ratio (iloperidone: mannitol is 12: 40) to mix homogeneously with mannitol 80g, particle size range controls to be less than 45 microns 99% by comminution by gas stream, and 90% is less than 20 microns, for subsequent use.Take the standby material 52g for subsequent use crushed, dry granulation is prepared into 20 order granules, for subsequent use; Take microcrystalline Cellulose 40g, acesulfame potassium 5g, mannitol 30g mix homogeneously again, dry granulation is prepared into 20 order granules, for subsequent use; Finally for subsequent use two kinds of granules are added acesulfame potassium 1g, Mint Essence 1g, cross-linked pvp 15g, magnesium stearate 3g, micropowder silica gel 1g, mix homogeneously, the heavy 148mg tabletting of controlled pressure 43N, sheet, theoretical amount is 1000.
Outward appearance: excellent
Mouthfeel: excellent
Embodiment 8:
The present embodiment prescription ratio (iloperidone: mannitol: acesulfame potassium is 12: 10: 2) takes iloperidone 24g, mannitol 20g, acesulfame potassium 4g mix homogeneously, particle size range controls to be less than 40 microns 99% by comminution by gas stream, 90% is less than 5 microns, for subsequent use.Take the material 24g for subsequent use crushed, dry granulation is prepared into 20 order granules, for subsequent use; Take microcrystalline Cellulose 10g, mannitol 2g, acesulfame potassium 1g mix homogeneously again, dry granulation is prepared into 20 order granules, for subsequent use; Finally for subsequent use two kinds of granules are added Mint Essence 1g, cross-linked pvp 4g, magnesium stearate 1g, micropowder silica gel 1g, mix homogeneously, the heavy 44mg tabletting of controlled pressure 39N, sheet, theoretical amount is 1000.
Outward appearance: general
Mouthfeel: good
Embodiment 9: stripping and disintegration time measure
Stripping assay method: the dissolving-out method with reference to about iloperidone sheet 12mg specification representation on FDA website: with 500ml0.1mol/l aqueous hydrochloric acid solution for dissolution medium, paddle method, rotating speed: 50 turns points, determines basic dissolving-out method.Specification be 12mg, 10mg, 8mg, 6mg, 4mg with 500ml0.1mol/l aqueous hydrochloric acid solution for dissolution medium, large agar diffusion method; Specification be 1,2 with 100ml0.1mol/l aqueous hydrochloric acid solution for dissolution medium, small-radius curve track; And with reference to Chinese Pharmacopoeia 2010 editions annex XC stripping II method slurry processes, rotating speed 50 turns, at 5 minutes, 10 minutes, 15 minutes, 30 minutes sampling and measuring release profiles.
Disintegration time assay method: get this product, with reference to dissolution method (Chinese Pharmacopoeia version in 2010 two annex XC first methods), the stainless steel mesh turning basket changes 20 order stainless steel meshs into, rotating speed is 50 turns per minute, with water 900ml for solvent, operate, timing from during tablet contact water, granule is disintegration time by the time of screen cloth completely in accordance with the law.
Measurement result sees the following form:
By the investigation analysis of the stripping of the sample that obtains each embodiment, disintegration time, the aspect such as outward appearance and mouthfeel, show that the iloperidone oral cavity disintegration tablet disintegrate that the present invention obtains is rapid, release is fast, disintegrate completely, can discharge completely in 10 minutes in 2 ~ 40 seconds, can onset in time, good mouthfeel, without grittiness, without sense of discomfort, substantially increase bioavailability, comply with the requirement of schizophrenic patients.And preparation technology is simple, be applicable to large-scale production.
Claims (2)
1. a preparation method for the oral cavity disintegration tablet of iloperidone, comprises step:
Take iloperidone 24g to mix homogeneously with mannitol 40g, particle size range controls to be less than 45 microns 99% by comminution by gas stream, and 90% is less than 20 microns, for subsequent use; Take the material 32g for subsequent use crushed, be prepared into 20 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Take microcrystalline Cellulose 20g, xylitol 30g mix homogeneously again, be prepared into 20 order granules with 5% hypromellose aqueous solution as bonding agent, dry for standby; Finally for subsequent use two kinds of granules are added aspartame 2g, flavoring orange essence 1g, crosslinked pvp8g, magnesium stearate 1g, micropowder silica gel 1g, mix homogeneously, the heavy 95mg tabletting of controlled pressure 45N, sheet, theoretical amount is 1000.
2. a preparation method for the oral cavity disintegration tablet of iloperidone, comprises step:
Take iloperidone 24g, mannitol 20g, acesulfame potassium 4g mix homogeneously, particle size range controls to be less than 40 microns 99% by comminution by gas stream, and 90% is less than 5 microns, for subsequent use; Take the material 24g for subsequent use crushed, dry granulation is prepared into 20 order granules, for subsequent use; Take microcrystalline Cellulose 10g, mannitol 2g, acesulfame potassium 1g mix homogeneously again, dry granulation is prepared into 20 order granules, for subsequent use; Finally for subsequent use two kinds of granules are added Mint Essence 1g, cross-linked pvp 4g, magnesium stearate 1g, micropowder silica gel 1g, mix homogeneously, the heavy 44mg tabletting of controlled pressure 39N, sheet, theoretical amount is 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110034683.9A CN102614140B (en) | 2011-01-26 | 2011-01-26 | Iloperidone oral cavity disintegration tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110034683.9A CN102614140B (en) | 2011-01-26 | 2011-01-26 | Iloperidone oral cavity disintegration tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102614140A CN102614140A (en) | 2012-08-01 |
| CN102614140B true CN102614140B (en) | 2015-11-25 |
Family
ID=46554594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110034683.9A Active CN102614140B (en) | 2011-01-26 | 2011-01-26 | Iloperidone oral cavity disintegration tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614140B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103099793B (en) * | 2013-02-06 | 2015-07-15 | 中国人民解放军第二军医大学 | Tablet and preparation method |
| CN104337783B (en) * | 2013-08-02 | 2018-06-22 | 山东新时代药业有限公司 | A kind of capecitabine tablet and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1613442A (en) * | 2003-11-06 | 2005-05-11 | 常州市第四制药厂有限公司 | Disintegrants for deodoring effectively and their preparation |
| CN101485636A (en) * | 2008-01-14 | 2009-07-22 | 齐鲁制药有限公司 | Risperidone orally disintegrating tablets and preparation method thereof |
| CN101822673A (en) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | Iloperidone-containing solid medicinal composition |
| CN101940561A (en) * | 2010-09-14 | 2011-01-12 | 浙江华海药业股份有限公司 | Quetiapine fumarate tablet and preparation method thereof |
| CN102440971A (en) * | 2010-10-15 | 2012-05-09 | 重庆市力扬医药开发有限公司 | Iloperidone orally disintegrating tablet |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2661683C (en) * | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
| AU2008359725A1 (en) * | 2008-07-24 | 2010-01-28 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
-
2011
- 2011-01-26 CN CN201110034683.9A patent/CN102614140B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1613442A (en) * | 2003-11-06 | 2005-05-11 | 常州市第四制药厂有限公司 | Disintegrants for deodoring effectively and their preparation |
| CN101485636A (en) * | 2008-01-14 | 2009-07-22 | 齐鲁制药有限公司 | Risperidone orally disintegrating tablets and preparation method thereof |
| CN101822673A (en) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | Iloperidone-containing solid medicinal composition |
| CN101940561A (en) * | 2010-09-14 | 2011-01-12 | 浙江华海药业股份有限公司 | Quetiapine fumarate tablet and preparation method thereof |
| CN102440971A (en) * | 2010-10-15 | 2012-05-09 | 重庆市力扬医药开发有限公司 | Iloperidone orally disintegrating tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102614140A (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201815384A (en) | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| CN101904824A (en) | Olanzapine orally-disintegrating tablet preparation and preparation method thereof | |
| CN103536568A (en) | Orally disintegrating tablets containing lurasidone and preparation method thereof | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN101756906B (en) | Pharmaceutical composition of cefcapene pivoxil hydrochloride granules and preparation method thereof | |
| CN103845298A (en) | Cefuroxime axetil dispersible tablet | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN103284968B (en) | Oral cavity disintegration tablet of a kind of aripiprazole composition microcrystalline and preparation method thereof | |
| CN102631331A (en) | Olanzapine oral disintegration tablet and preparation method thereof | |
| CN103284962A (en) | Moxifloxacin dispersible tablet and preparation method thereof | |
| CN102327244B (en) | Ambroxol hydrochloride orally disintegrating tablet and preparation method thereof | |
| CN104510717B (en) | Olanzapine orally-disintegrating tablet and preparation method thereof | |
| CN108261399A (en) | Olanzapine oral disnitegration tablet and preparation method thereof | |
| CN102614140B (en) | Iloperidone oral cavity disintegration tablet and preparation method thereof | |
| CN110200929A (en) | A kind of oral tablet and preparation method thereof containing terbinafine HCl | |
| CN104887634A (en) | Olanzapine orally disintegrating tablets and preparation method thereof | |
| CN103301467A (en) | Stable taste-masking ambroxol hydrochloride compound and preparation method thereof | |
| CN101822646B (en) | Fexofenadine hydrochloride orally disintegrating tablet and preparation method thereof | |
| CN102860986A (en) | Stable taste-masking levocetirizine medicine composition and preparation method thereof | |
| JPWO2020090970A1 (en) | Pharmaceutical composition containing an antitumor agent | |
| CN103720672B (en) | Montelukast sodium chewable tablet and direct powder compression preparation method thereof | |
| CN103271886B (en) | Pirfenidone tablet and preparation method thereof | |
| CN103007286A (en) | Solid medicine composition of tolvaptan | |
| CN102048705B (en) | Palonosetron hydrochloride orally disintegrating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 310018 room 103, first floor, building 2, Heke science and technology center, No. 500 QiaoXin Road, Xiasha street, Hangzhou Economic and Technological Development Zone, Zhejiang Province Patentee after: Zhejiang Jiuzhou biomedical Co.,Ltd. Address before: 310051 fifth floor, building 4, No. 88, Jiangling Road, Hangzhou, Zhejiang Patentee before: ZHEJIANG JIUZHOU PHARMA SCIENCE & TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211022 Address after: 318000 No. 58 Binhai Road, Jiaojiang District, Taizhou City, Zhejiang Province Patentee after: Zhejiang Siwei Pharmaceutical Technology Co.,Ltd. Address before: 310018 room 103, first floor, building 2, Heke science and technology center, No. 500 QiaoXin Road, Xiasha street, Hangzhou Economic and Technological Development Zone, Zhejiang Province Patentee before: Zhejiang Jiuzhou biomedical Co.,Ltd. |